BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20460771)

  • 1. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.
    Endo S; Matsunaga T; Soda M; Tajima K; Zhao HT; El-Kabbani O; Hara A
    Biol Pharm Bull; 2010; 33(5):886-90. PubMed ID: 20460771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis.
    Matsunaga T; Endo S; Soda M; Zhao HT; El-Kabbani O; Tajima K; Hara A
    Biochem Biophys Res Commun; 2009 Nov; 389(1):128-32. PubMed ID: 19706287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
    Takemura M; Endo S; Matsunaga T; Soda M; Zhao HT; El-Kabbani O; Tajima K; Iinuma M; Hara A
    J Nat Prod; 2011 May; 74(5):1201-6. PubMed ID: 21561086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
    Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
    Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
    Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
    Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of aldo-keto reductase family 1 member B10 by unsaturated fatty acids.
    Hara A; Endo S; Matsunaga T; Soda M; El-Kabbani O; Yashiro K
    Arch Biochem Biophys; 2016 Nov; 609():69-76. PubMed ID: 27665999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
    Soda M; Hu D; Endo S; Takemura M; Li J; Wada R; Ifuku S; Zhao HT; El-Kabbani O; Ohta S; Yamamura K; Toyooka N; Hara A; Matsunaga T
    Eur J Med Chem; 2012 Feb; 48():321-9. PubMed ID: 22236472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
    Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
    FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
    Endo S; Matsunaga T; Mamiya H; Ohta C; Soda M; Kitade Y; Tajima K; Zhao HT; El-Kabbani O; Hara A
    Arch Biochem Biophys; 2009 Jul; 487(1):1-9. PubMed ID: 19464995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human aldose reductase-like protein (AKR1B10) by α- and γ-mangostins, major components of pericarps of mangosteen.
    Soda M; Endo S; Matsunaga T; Zhao HT; El-Kabbani O; Iinuma M; Yamamura K; Hara A
    Biol Pharm Bull; 2012; 35(11):2075-80. PubMed ID: 23123477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10.
    Endo S; Hu D; Suyama M; Matsunaga T; Sugimoto K; Matsuya Y; El-Kabbani O; Kuwata K; Hara A; Kitade Y; Toyooka N
    Bioorg Med Chem; 2013 Nov; 21(21):6378-84. PubMed ID: 24071447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
    Endo S; Matsunaga T; Kuwata K; Zhao HT; El-Kabbani O; Kitade Y; Hara A
    Bioorg Med Chem; 2010 Apr; 18(7):2485-90. PubMed ID: 20304656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10.
    Zhang W; Wang L; Zhang L; Chen W; Chen X; Xie M; Yan G; Hu X; Xu J; Zhang J
    Steroids; 2014 Aug; 86():39-44. PubMed ID: 24793566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of human aldehyde reductase: characterization of the active site pocket.
    Barski OA; Gabbay KH; Grimshaw CE; Bohren KM
    Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
    Cousido-Siah A; Ruiz FX; Mitschler A; Porté S; de Lera ÁR; Martín MJ; Manzanaro S; de la Fuente JA; Terwesten F; Betz M; Klebe G; Farrés J; Parés X; Podjarny A
    Acta Crystallogr D Biol Crystallogr; 2014 Mar; 70(Pt 3):889-903. PubMed ID: 24598757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10.
    Cousido-Siah A; Ruiz FX; Crespo I; Porté S; Mitschler A; Parés X; Podjarny A; Farrés J
    Chem Biol Interact; 2015 Jun; 234():290-6. PubMed ID: 25532697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
    Gallego O; Ruiz FX; Ardèvol A; Domínguez M; Alvarez R; de Lera AR; Rovira C; Farrés J; Fita I; Parés X
    Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20764-9. PubMed ID: 18087047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde.
    Ruiz FX; Moro A; Gallego O; Ardèvol A; Rovira C; Petrash JM; Parés X; Farrés J
    Chem Biol Interact; 2011 May; 191(1-3):199-205. PubMed ID: 21329680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for the inhibition of AKR1B10 by the C3 brominated TTNPB derivative UVI2008.
    Ruiz FX; Crespo I; Álvarez S; Porté S; Giménez-Dejoz J; Cousido-Siah A; Mitschler A; de Lera ÁR; Parés X; Podjarny A; Farrés J
    Chem Biol Interact; 2017 Oct; 276():174-181. PubMed ID: 28161411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
    Huang L; He R; Luo W; Zhu YS; Li J; Tan T; Zhang X; Hu Z; Luo D
    Recent Pat Anticancer Drug Discov; 2016; 11(2):184-96. PubMed ID: 26844556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.